We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intrexon (XON) Q4 Loss Wider than Expected, Revenues Lag
Read MoreHide Full Article
Shares of Intrexon Corporation rose more than 8% on Mar 2, since it announced its fourth-quarter 2016 results. However, on a year-to-date basis, shares of the company have lost 3.1%, while the Zacks classified Medical-Medical Services industry gained 7.5%.
Intrexon reported adjusted loss per share of 26 cents in the fourth quarter of 2016. Adjusted loss excluded shares issued as compensation for services bad debt expense and equity in net loss of affiliates. In fact, this loss was wider than the Zacks Consensus Estimate loss of 23 cents.
Total revenue came in at $46 million in the quarter, up 11% year over year. Reported revenues were, however, below the Zacks Consensus Estimate of $52 million.
Quarter in Detail
Intrexon’s revenues primarily consist of collaboration and licensing revenues as well as product and service revenues.
Collaboration and licensing revenues increased 31.2% to $27.7 million. While product revenues came in at $7.7 million, down 16.7% from the year-ago period, service revenues came in at $10.3 million, down 4.2% year over year.
Intrexon follows a business model under which it commercializes its technologies through exclusive channel collaborations (ECC), licensing agreements and joint ventures with collaborators that have market and product development expertise as well as sales and marketing capabilities to bring new and improved products and processes to market. Such agreements provide the company with funds in the form of technology access fees along with milestones and other payments.
Intrexon is also developing several candidates in partnership with other companies.
During 2016, the FDA granted Fast Track designation to Fibrocel Science, Inc. for FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa as well as to Oragenics, Inc. (OGEN - Free Report) for ActoBiotics AG013 for the treatment of oral mucositis. Also, the FDA granted Orphan Drug designation to Agilis Biotherapeutics' AGIL-FA for the treatment of Friedreich's ataxia as well as to Fibrocell’s FCX-013 for the treatment of linear scleroderma. Moving ahead, we expect investors’ focus to remain on further developmental updates by the company.
2016 Results
For 2016, adjusted loss came in at 76 cents per share.
Revenues came in at $190.9 million, which is an increase of 10% year over year.
Sunesis’ loss estimates narrowed by 5.06% and 8.80% for 2016 and 2017, respectively, over the past 30 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 0.54%.
Intrexon Corporation Price, Consensus and EPS Surprise
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Intrexon (XON) Q4 Loss Wider than Expected, Revenues Lag
Shares of Intrexon Corporation rose more than 8% on Mar 2, since it announced its fourth-quarter 2016 results. However, on a year-to-date basis, shares of the company have lost 3.1%, while the Zacks classified Medical-Medical Services industry gained 7.5%.
Intrexon reported adjusted loss per share of 26 cents in the fourth quarter of 2016. Adjusted loss excluded shares issued as compensation for services bad debt expense and equity in net loss of affiliates. In fact, this loss was wider than the Zacks Consensus Estimate loss of 23 cents.
Total revenue came in at $46 million in the quarter, up 11% year over year. Reported revenues were, however, below the Zacks Consensus Estimate of $52 million.
Quarter in Detail
Intrexon’s revenues primarily consist of collaboration and licensing revenues as well as product and service revenues.
Collaboration and licensing revenues increased 31.2% to $27.7 million.
While product revenues came in at $7.7 million, down 16.7% from the year-ago period, service revenues came in at $10.3 million, down 4.2% year over year.
Intrexon follows a business model under which it commercializes its technologies through exclusive channel collaborations (ECC), licensing agreements and joint ventures with collaborators that have market and product development expertise as well as sales and marketing capabilities to bring new and improved products and processes to market. Such agreements provide the company with funds in the form of technology access fees along with milestones and other payments.
Intrexon is also developing several candidates in partnership with other companies.
During 2016, the FDA granted Fast Track designation to Fibrocel Science, Inc. for FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa as well as to Oragenics, Inc. (OGEN - Free Report) for ActoBiotics AG013 for the treatment of oral mucositis. Also, the FDA granted Orphan Drug designation to Agilis Biotherapeutics' AGIL-FA for the treatment of Friedreich's ataxia as well as to Fibrocell’s FCX-013 for the treatment of linear scleroderma. Moving ahead, we expect investors’ focus to remain on further developmental updates by the company.
2016 Results
For 2016, adjusted loss came in at 76 cents per share.
Revenues came in at $190.9 million, which is an increase of 10% year over year.
Zacks Rank & Key Picks
Intrexon is a Zacks Rank #3 (Hold) stock. Another better-ranked stocks in the health care sector includes Sunesis Pharmaceuticals which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Sunesis’ loss estimates narrowed by 5.06% and 8.80% for 2016 and 2017, respectively, over the past 30 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 0.54%.
Intrexon Corporation Price, Consensus and EPS Surprise
Intrexon Corporation Price, Consensus and EPS Surprise | Intrexon Corporation Quote
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>